Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect

J Antimicrob Chemother. 2020 Oct 1;75(10):3084-3086. doi: 10.1093/jac/dkaa253.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Betacoronavirus*
  • COVID-19
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / metabolism*
  • Cytochrome P-450 CYP3A Inhibitors / administration & dosage
  • Cytochrome P-450 CYP3A Inhibitors / metabolism*
  • Drug Interactions / physiology*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Lopinavir / administration & dosage
  • Lopinavir / metabolism*
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / metabolism*
  • Ritonavir / administration & dosage
  • Ritonavir / metabolism*
  • SARS-CoV-2
  • Time Factors
  • Withholding Treatment / trends
  • Young Adult

Substances

  • Cytochrome P-450 CYP3A Inhibitors
  • Lopinavir
  • Ritonavir